Of note, KCa3.1 blockade reduced several aspects of TGFβ1-dependent EMT, suggesting that KCa3.1 blockers may reduce airway wall fibrosis in asthma and COPD. The gene discussed is KCNN4; the disease is chronic obstructive pulmonary disease.